Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Paul K, Flanagan"'
Autor:
Jennifer Kelly, Miran Al-Rammahi, Kristian Daly, Paul K. Flanagan, Arun Urs, Marta C. Cohen, Gabriella di Stefano, Marcel J. C. Bijvelds, David N. Sheppard, Hugo R. de Jonge, Ursula E. Seidler, Soraya P. Shirazi-Beechey
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-17 (2022)
Abstract Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Defective CFTR leads to accumulation of dehydrated viscous mucus within the small intestine, luminal acidification and altere
Externí odkaz:
https://doaj.org/article/839c5ac368f2469ea3deaf9f54353d59
Autor:
Joseph, Fiske, Eleanor, Liu, Jimmy K, Limdi, Thomas E, Conley, Tristan, Townsend, Mike, Davies, Robert, Brockwell, Daniyal, Baig, Sherif, Abdelbadiee, Anastasia, Uney, Angela, Liaros, Waqas, Gaba, Philip J, Smith, Paul K, Flanagan, Sreedhar, Subramanian
Publikováno v:
European Journal of Gastroenterology & Hepatology. 34:1132-1139
Anti-tumour necrosis factor (TNF) agents are associated with increased infection risk among elderly IBD patients, but little is known about non anti-TNF biologics in this cohort. We examined the safety and effectiveness of ustekinumab in elderly Croh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4833f748a89047626ab8b6d466679f7
https://doi.org/10.1097/meg.0000000000002436
https://doi.org/10.1097/meg.0000000000002436
Autor:
Gerum Gashaw Gebeyehu, Joseph Fiske, Eleanor Liu, Jimmy K. Limdi, Giacomo Broglio, Christian Selinger, Violeta Razsanskaite, Philip J. Smith, Paul K. Flanagan, Sreedhar Subramanian
Publikováno v:
Digestive diseases and sciences.
Anti-tumour necrosis factor (anti-TNF) agents are associated with increased infection risk among elderly inflammatory bowel disease (IBD) patients, and thus, alternative biologics may be preferable. However, little comparative data exist on the safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c410eb9227de725433ec2f1bd541cb18
https://pubmed.ncbi.nlm.nih.gov/36436155
https://pubmed.ncbi.nlm.nih.gov/36436155
Autor:
Paul K Flanagan, Violeta Razanskaite, Jimmy K. Limdi, William Jakobek, James Colclough, Thomas Conley, Eleanor Liu, Sreedhar Subramanian
Publikováno v:
Posters.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::862890267e131ffeabc09c1319a9d1fa
https://doi.org/10.1136/gutjnl-2021-bsg.162
https://doi.org/10.1136/gutjnl-2021-bsg.162
Autor:
Sreedhar Subramanian, Jonathan M. Rhodes, Tariq Iqbal, Paul K Flanagan, Kate Martin, John C. Mansfield, Chris Probert, Miles Parkes, Helen Dallal, Kate Culshaw, Jeffrey Butterworth, Graham W. Horgan, Ailsa Hart
Publikováno v:
Digestive Diseases and Sciences
BACKGROUND: Increased mucosa-associated E. coli are present in Crohn's disease, but their role in pathogenesis is uncertain. AIMS: To assess efficacy and safety of an antibiotic/hydroxychloroquine combination effective against E. coli inside macropha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9384a2ae721dd4e630c48306c82d43d7
Autor:
Michael Davies, Sreedhar Subramanian, Ian Reilly, Christopher Watters, Mira Swaminathan, Stephanie Michail, James Morgan, Tristan Townsend, Paul K Flanagan, Violeta Razanskaite, Daniel Storey, Douglas Penman
Publikováno v:
Posters.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65a2b706d3ad9ce4b713618d0c7e7110
https://doi.org/10.1136/gutjnl-2020-bsgcampus.237
https://doi.org/10.1136/gutjnl-2020-bsgcampus.237
Autor:
Paul K Flanagan, Jonathan M. Rhodes, Sreedhar Subramanian, Kate Culshaw, Tariq Iqbal, Miles Parkes, John C. Mansfield, Jeff Butterworth, Chris Probert, Kate Martin, Helen Dallal, Ailsa Hart, Graham W. Horgan
Publikováno v:
Oral.
Introduction Mucosal E. coli are increased in Crohn’s disease (CD). They replicate within macrophages and are then inaccessible to penicillins and gentamicin. Hydroxychloroquine is used with doxycycline to treat Whipple’s disease. It raises macro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2296a0c016dea4a6607219ead8fcb36
https://doi.org/10.1136/gutjnl-2020-bsgcampus.8
https://doi.org/10.1136/gutjnl-2020-bsgcampus.8
Autor:
Philip J. Smith, Lisa Critchley, Daniel Storey, Belle Gregg, June E. Stenson, Andrew Kneebone, Tracy Rimmer, Stevena E. Burke, Shamas Hussain, Wan Yi Teoh, Stephan Vazeille, Solange Serna, Alan Steel, Edmund Derbyshire, Paul Collins, Martyn Dibb, Paul K. Flanagan, Christopher Probert, Ajay M. Verma, Sreedhar Subramanian
Publikováno v:
Gastroenterology. 162:S-89
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12f0479c915ad75f585ffb1fd3062c4b
https://doi.org/10.1016/s0016-5085(22)60226-9
https://doi.org/10.1016/s0016-5085(22)60226-9
Autor:
Adam Chapman, Philip J Smith, Sreedhar Subramanian, Violeta Razanskaite, Daniel Storey, Douglas Penman, Mira Swaminathan, Joseph Sabine, Keith Bodger, Paul K Flanagan, Tristan Townsend, Ian Reilly, Michael Davies, James Morgan, Stephanie Michail, Susanna Dodd, Christopher Watters
Publikováno v:
Alimentary Pharmacology and Therapeutics
Background Anti-tumour necrosis factor (TNF) agents are effective in Crohn's disease but some patients lose response and require alternative biologic therapy. There are few data on comparative effectiveness of vedolizumab and ustekinumab in this sett
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba7ab2288a05add4df80a2ac02c8f8c4
https://doi.org/10.1111/apt.16057
https://doi.org/10.1111/apt.16057
Autor:
Sreedhar Subramanian, Jonathan M. Rhodes, C.S.J. Probert, Kate Culshaw, Tariq Iqbal, Miles Parkes, Paul K Flanagan, John C. Mansfield, Kate Martin, Jeff Butterworth, Helen Dallal, Andrew Hart, Graham W. Horgan
Publikováno v:
Journal of Crohn's and Colitis. 14:S487-S487
Background Mucosal E. coli are increased in Crohn’s disease (CD). They replicate within macrophages where they are inaccessible to penicillins and gentamicin. Hydroxychloroquine is successfully used together with doxycycline, typically for 12 month
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a19d37112f2dd275373bff04e2a8dda2
https://doi.org/10.1093/ecco-jcc/jjz203.707
https://doi.org/10.1093/ecco-jcc/jjz203.707